In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...
Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...
Biomerica (BMRA) announces that its food intolerance products for Crohn’s Disease and Ulcerative Colitis have achieved CE-marking under the ...
Focus on Precision Medicine: Certification covers Biomerica’s food intolerance products developed to support patients with Crohn’s Disease and Ulcerative Colitis (UC), both of which are chronic and ...
Clinical outcomes for ulcerative colitis patients with a prior anti-TNF therapy failure appeared similar with ustekinumab ...
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...
A British study found that virtual chromoendoscopy has a higher neoplasia detection rate than other endoscopic modalities ...
Coffee by itself does not irritate ulcerative colitis. But this caffeine drink can stimulate the colon, which can be more uncomfortable for those living with the condition. Share on Pinterest ...
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
Larry Sears and Sally Zlotnick Sears recently donated $1 million to the Crohn’s and Colitis Foundation, according to a news release.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results